Text Size

Alprostadil in Maculopathy Study (AIMS)

This study has been terminated.
(Interim Analysis: Optimization of study design required.)
Sponsor:
Information provided by (Responsible Party):
UCB, Inc.
ClinicalTrials.gov Identifier:
NCT00619229
First received: December 24, 2007
Last updated: November 29, 2011
Last verified: November 2011
History of Changes
Results First Received: January 27, 2011  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Investigator);   Primary Purpose: Treatment
Condition: Macular Degeneration
Interventions: Drug: Alprostadil (prostaglandin E1)
Other: Placebo

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations

The Full Analysis Set (FAS) includes all randomized subjects treated with at least one infusion and having valid Baseline and Post-Baseline measurements.

The Randomized Set (RS) consists of all randomized subjects who have completed Visit 16 or terminated prematurely.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Participant Flow shows the RS. Baseline Characteristics refer to the FAS.

Reporting Groups
  Description
Alprostadil Alprostadil 60 mcg/day i.v. for 15 days
Placebo Placebo i.v. for 15 days

Participant Flow:   Overall Study
    Alprostadil     Placebo  
STARTED     18     18  
Full Analysis Set (FAS)     16     17  
COMPLETED     14     16  
NOT COMPLETED     4     2  
Withdrawal by Subject                 1                 1  
Lost to Follow-up                 1                 0  
Termination of the Study by the Sponsor                 1                 1  
Investigator planned Cataract Operation                 1                 0  



  Baseline Characteristics
  Hide Baseline Characteristics

Reporting Groups
  Description
Alprostadil Alprostadil 60 mcg/day i.v. for 15 days
Placebo Placebo i.v. for 15 days
Total Total of all reporting groups

Baseline Measures
    Alprostadil     Placebo     Total  
Number of Participants  
[units: participants]
 		  16     17     33  
Age  
[units: participants]
 		     
<=18 years     0     0     0  
Between 18 and 65 years     1     4     5  
>=65 years     15     13     28  
Age  
[units: years]
Mean ± Standard Deviation 		  76.1  ± 8.5     71.7  ± 8.1     73.8  ± 8.5  
Gender  
[units: participants]
 		     
Female     6     9     15  
Male     10     8     18  
White  
[units: participants]
 		  16     17     33  
Weight  
[units: kilogramm (kg)]
Mean ± Standard Deviation 		  77.14  ± 14.71     76.46  ± 14.49     76.79  ± 14.37  
Height (cm)  
[units: centimeter (cm)]
Mean ± Standard Deviation 		  171.06  ± 9.29     168.59  ± 8.69     169.79  ± 8.93  
Body Mass Index (BMI)  
[units: kg/ (m^2)]
Mean ± Standard Deviation 		  26.20  ± 3.38     26.70  ± 3.32     26.45  ± 3.31  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Difference in Visual Acuity Between Measurements at 3 Months After Drug Intervention and Measurements at Baseline (Assessed Within Early Treatment Diabetic Retinopathy Study (ETDRS) Chart)   [ Time Frame: From baseline to 3 months ]
  Show Outcome Measure 1

2.  Secondary:   The Difference in Visual Acuity Between Measurements Immediately After Intervention and Measurements at Baseline   [ Time Frame: From baseline to time immediately after intervention ]
  Show Outcome Measure 2

3.  Secondary:   The Difference in Visual Acuity Between Measurements at 6 Months After Intervention and Measurements at Baseline   [ Time Frame: From baseline to 6 months ]
  Show Outcome Measure 3

4.  Secondary:   Progression of the Dry Age-related Macular Degeneration   [ Time Frame: From baseline to 6 months ]
  Show Outcome Measure 4

5.  Secondary:   Development of a Wet Age-related Macular Degeneration   [ Time Frame: From baseline to 6 months ]
  Show Outcome Measure 5

6.  Secondary:   The Difference in Contrast Sensitivity Between Measurements Immediately After Intervention and Measurements at Baseline   [ Time Frame: From baseline to time immediately after intervention ]
  Show Outcome Measure 6

7.  Secondary:   The Difference in Contrast Sensitivity Between Measurements at 3 Months After Intervention and Measurements at Baseline   [ Time Frame: From baseline to 3 months ]
  Show Outcome Measure 7

8.  Secondary:   The Difference in Contrast Sensitivity Between Measurements at 6 Months After Intervention and Measurements at Baseline   [ Time Frame: From baseline to 6 months ]
  Show Outcome Measure 8

9.  Secondary:   The Difference in Color Vision Between Measurements Immediately After Intervention and Measurements at Baseline   [ Time Frame: From baseline to time immediately after intervention ]
  Show Outcome Measure 9

10.  Secondary:   The Difference in Color Vision Between Measurements at 3 Months After Intervention and Measurements at Baseline   [ Time Frame: From baseline to 3 months ]
  Show Outcome Measure 10

11.  Secondary:   The Difference in Color Vision Between Measurements at 6 Months After Intervention and Measurements at Baseline   [ Time Frame: From baseline to 6 months ]
  Show Outcome Measure 11


  Serious Adverse Events
  Show Serious Adverse Events


  Other Adverse Events
  Show Other Adverse Events


  More Information
  Show More Information